KRON Kronos Bio, Inc. revenue, earnings and financials
For the quarter ended March 31, 2025, Kronos Bio, Inc. reported revenue of $1.86M (down 26.0% from a year earlier), net income of −$8.36M and diluted EPS of −$0.14; over the last four quarters revenue was $9.19M and net income −$64.5M; for the fiscal year ended December 2024 revenue was $9.85M, up 56.6% on the year before.
KRON annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $9.85M, gross profit n/a, operating income −$92.9M, net income −$86.1M (margin -874.1%), EPS −$1.43
- Fiscal year ended Dec 2023: revenue $6.29M, gross profit n/a, operating income −$122M, net income −$113M (margin -1791.9%), EPS −$1.95
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$137M, net income −$133M (margin n/a), EPS −$2.37
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$151M, net income −$151M (margin n/a), EPS −$2.76
KRON quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue $1.86M (down 26.0% year over year), net income −$8.36M, EPS −$0.14
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.27M (down 0.7% year over year), net income −$25.8M, EPS −$0.43
- Quarter ended Sep 30, 2024: revenue $2.37M (up 158.5% year over year), net income −$14.1M, EPS −$0.23
- Quarter ended Jun 30, 2024: revenue $2.69M (up 44.2% year over year), net income −$16.2M, EPS −$0.27
- Quarter ended Mar 31, 2024: revenue $2.52M (up 106.4% year over year), net income −$30.0M, EPS −$0.50
- Quarter ended Dec 31, 2023 (from the annual report): revenue $2.29M, net income −$25.3M, EPS −$0.43
- Quarter ended Sep 30, 2023: revenue $917K, net income −$31.4M, EPS −$0.54
- Quarter ended Jun 30, 2023: revenue $1.86M, net income −$29.7M, EPS −$0.52
- Quarter ended Mar 31, 2023: revenue $1.22M, net income −$26.2M, EPS −$0.46
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$31.8M, EPS −$0.56
- Quarter ended Sep 30, 2022: revenue $0, net income −$32.3M, EPS −$0.57
- Quarter ended Jun 30, 2022: revenue $0, net income −$32.9M, EPS −$0.59
- Quarter ended Mar 31, 2022: revenue $0, net income −$36.3M, EPS −$0.65
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$62.3M, EPS −$1.14
- Quarter ended Sep 30, 2021: revenue n/a, net income −$33.6M, EPS −$0.61
- Quarter ended Jun 30, 2021: revenue n/a, net income −$29.1M, EPS −$0.53
- Quarter ended Mar 31, 2021: revenue n/a, net income −$26.1M, EPS −$0.48
KRON cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$65.4M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$78.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$90.9M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$118M, share buybacks n/a
KRON balance sheet
- Mar 31, 2025: cash $91.6M, total assets $108M, total liabilities $28.3M, shareholders' equity $79.8M
- Dec 31, 2024: cash $84.6M, total assets $124M, total liabilities $36.8M, shareholders' equity $87.6M
- Sep 30, 2024: cash $75.0M, total assets $150M, total liabilities $38.9M, shareholders' equity $111M
- Jun 30, 2024: cash $70.2M, total assets $164M, total liabilities $41.1M, shareholders' equity $123M
- Mar 31, 2024: cash $46.2M, total assets $183M, total liabilities $46.0M, shareholders' equity $137M
- Dec 31, 2023: cash $64.3M, total assets $213M, total liabilities $54.2M, shareholders' equity $159M
- Sep 30, 2023: cash $57.6M, total assets $238M, total liabilities $59.4M, shareholders' equity $179M
- Jun 30, 2023: cash $44.4M, total assets $261M, total liabilities $57.3M, shareholders' equity $203M
What is KRON's revenue?
Kronos Bio, Inc. reported $9.19M of revenue over its last four quarters, through March 31, 2025.
Is KRON profitable?
No. Kronos Bio, Inc. lost $64.5M over the last four quarters.
What is KRON's EPS?
Diluted earnings per share over the last four quarters were −$1.07; −$0.14 in the latest quarter.